240 related articles for article (PubMed ID: 3914173)
1. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
[TBL] [Abstract][Full Text] [Related]
2. Alpha-interferon in polycythemia vera and essential thrombocythemia.
Turri D; Mitra ME; Di Trapani R; Lipari MG; Perricone R; Cajozzo A
Haematologica; 1991; 76(1):75-7. PubMed ID: 2055565
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interferon-alpha therapy of Philadelphia chromosome-negative myeloproliferative disorders with thrombocytosis.
Talpaz M; Kurzrock R; Kantarjian H; O'Brien S; Gutterman JU
Am J Med; 1989 May; 86(5):554-8. PubMed ID: 2712063
[TBL] [Abstract][Full Text] [Related]
4. Interferon in the treatment of myeloproliferative diseases.
Silver RT
Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
[TBL] [Abstract][Full Text] [Related]
5. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
6. Recombinant alpha-2a interferon (alpha-IFN) in the treatment of essential thrombocythaemia. Preliminary report.
Gugliotta L; Macchi S; Catani L; Chetti L; Mattioli Belmonte M; Guarini A; Criscuolo D; Tura S
Haematologica; 1987; 72(3):277-9. PubMed ID: 3114099
[No Abstract] [Full Text] [Related]
7. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.
Ludwig H; Cortelezzi A; Van Camp BG; Polli E; Scheithauer W; Kuzmits R; Linkesch W; Gisslinger H; Sinzinger H; Fritz E
Oncology; 1985; 42 Suppl 1():19-25. PubMed ID: 4080297
[TBL] [Abstract][Full Text] [Related]
8. [Interferon therapy in essential thrombocythemia].
Seewann HL
Wien Med Wochenschr; 1993; 143(16-17):420-4. PubMed ID: 8273365
[TBL] [Abstract][Full Text] [Related]
9. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
10. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
11. Efficacy trial of pipobroman in essential thrombocythemia: a study of 24 patients.
Brusamolino E; Canevari A; Salvaneschi L; Merante S; Bernasconi C
Cancer Treat Rep; 1984 Nov; 68(11):1339-42. PubMed ID: 6541969
[TBL] [Abstract][Full Text] [Related]
12. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Olesen LH; Pedersen BB
Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
[TBL] [Abstract][Full Text] [Related]
13. [Interferon (IFN) therapy (recombinant IFN-alpha-2C or recombinant IFN-gamma) in metastasized hypernephroma].
Kuzmits R; Scheithauer W; Ludwig H; Flener R
Acta Med Austriaca; 1985; 12(5):129-34. PubMed ID: 3938590
[TBL] [Abstract][Full Text] [Related]
14. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
15. Introduction and overview of interferon alfa in myeloproliferative and hemangiomatous diseases.
Appelbaum FR
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-5. PubMed ID: 2197729
[TBL] [Abstract][Full Text] [Related]
16. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
17. [Use of interferon in patients with hairy cell leukemia and myeloproliferative disorders].
Skotnicki AB; Wolska-Smoleń T
Acta Haematol Pol; 1994; 25(2 Suppl 1):124-35. PubMed ID: 8067197
[TBL] [Abstract][Full Text] [Related]
18. Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Saba R; Jabbour E; Giles F; Cortes J; Talpaz M; O'Brien S; Freireich EJ; Garcia-Manero G; Kantarjian H; Verstovsek S
Cancer; 2005 Jun; 103(12):2551-7. PubMed ID: 15861412
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alfa corrects thrombocytosis in patients with myeloproliferative disorders.
Ludwig H; Linkesch W; Gisslinger H; Fritz E; Sinzinger H; Radaszkiewicz T; Chott A; Flener R; Micksche M
Cancer Immunol Immunother; 1987; 25(3):266-73. PubMed ID: 3677127
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.
Radin AI; Kim HT; Grant BW; Bennett JM; Kirkwood JM; Stewart JA; Hahn RG; Dutcher JP; Wiernik PH; Oken MM;
Cancer; 2003 Jul; 98(1):100-9. PubMed ID: 12833462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]